1、Vaccines and Related Biological Products Advisory Committee Meeting July 23, 2009 Pandemic Influenza A (H1N1) Virology Update Nancy Cox, PhD Alexander Klimov, PhD Influenza Division National Center for Immunizations and Respiratory Diseases Centers for Disease Control and Prevention,BEGINNING OF THE
2、 2009 H1N1 PANDEMIC,Garten, et al. Science Express 2009,HOST AND LINEAGE ORIGINS FOR THE GENE SEGMENTS OF THE 2009 A(H1N1) VIRUS,REASSORTANT EVENTS AMONG SWINE INFLUENZA VIRUSES (SIV) IN NORTH AMERICA,ORIGIN OF THE 2009 PANDEMIC H1N1 VIRUS,Evolutionary Relationships Among 2009 Pandemic Influenza A (
3、H1N1) Hemagglutinin (HA) Genes,Evolutionary Relationships Among 2009 Pandemic Influenza A (H1N1) Neuraminidase Genes,GENETIC DISTANCE BETWEEN A/NEW JERSEY/8/1976 AND A/TEXAS/05/2009 COMPARING WITH H3N2 VIRUSES,HI REACTIONS OF PANDEMIC INFLUENZA H1N1v VIRUSES (CDC),HI REACTIONS OF PANDEMIC INFLUENZA
4、H1N1v VIRUSES (NIMR),HI REACTIONS OF PANDEMIC INFLUENZA H1N1v VIRUSES (NIID),COUNTRIES FOR WHICH SEQUENCING OR ANTIGENIC DATA ARE AVAILABLE,RESISTANCE OF PANDEMIC INFLUENZA H1N1v VIRUSES TO ADAMANTANES (M2 BLOCKERS),Five oselatmivir-resistant cases were recently documented:Denmark (after oseltamivir
5、 treatment)Japan (2) (after oseltamivir treatment)Canada (after oseltamivir treatment)Hong Kong (travel from U.S., no treatment),RESISTANCE OF PANDEMIC INFLUENZA H1N1v VIRUSES TO NEURAMINIDASE INHIBITORS,SERUM CROSS-REACTIVE ANTIBODY RESPONSE TO A NOVEL INFLUENZA A(H1N1) VIRUS AFTER VACCINATION WITH
6、 SEASONAL INFLUENZA VACCINES (MMWR MAY 2009),SERUM CROSS-REACTIVE ANTIBODY RESPONSE TO A NOVEL INFLUENZA A(H1N1) VIRUS AFTER VACCINATION WITH SEASONAL INFLUENZA VACCINES (MMWR MAY 2009),IMMUNITY TO 2009 H1N1 VIRUS RESULTING FROM PRIOR INFLUENZA INFECTION OR VACCINATION WITH SEASONAL INFLUENZA VACCIN
7、E IN DIFFERENT AGE GROUPS (NEJM submitted),Less than 4% of individuals born during or after 1980 exhibited preexisting, cross-reactive, neutralizing antibody titers of 40 to the pandemic virus, whereas 34% of individuals born prior to 1950 had titers of 80Vaccination with recent seasonal trivalent i
8、nfluenza vaccines (TIV), resulted in a 4-fold rises in cross-reactive antibody to the pandemic virus in only 2% of children aged 6 months to 9 years, 12-22% of adults aged 18-64 years, and 60 yearsSeasonal TIV with adjuvant induced similar cross-reactive antibody responses; no increase in cross-reac
9、ting antibody to pandemic H1N1 virus,CONCLUSIONS,All 2009 pandemic H1N1 viruses are antigenically similar to A/California/7/2009Minor genetic variabilityNo evidence of reassortment with seasonal or H5N1virusesResistant to M2 blockers Sensitive to NI (oseltamivir and zanamavir) Oseltamivir-resistant
10、documented (4 of 5 after treatment or prophylaxis)Vaccination with contemporary seasonal influenza vaccines, with or without an adjuvant, induces little or no cross-reactive antibody to the 2009 pandemic H1N1 virus in any age group Individuals 30 years of age are serologically “nave” A proportion of
11、 older adults appear to have pre-existing, cross-reactive antibodies,CONCLUSIONS,Genetic and antigenic characterization of viruses, serologic assays, animal models, and epidemiologic assessments - all critical components for public health risk assessment Substantial consistency between laboratory an
12、d epidemiologic results Suggest novel H1N1 may not be fully adapted to humans Epidemiologic and virologic surveillance are important for identification of future changes in Antigenic characteristics Transmission characteristics Severity of disease Antiviral resistance Intensity (surge) in US cases L
13、imited understanding of diversity of influenza viruses in pigs globally is a major gap in pandemic preparedness USDAs efforts to initiate surveillance should be supported and encouraged by public health, putting “One Health” concept into action Ensuring virus sharing public health, animal health, ac
14、ademia and industry is a key component of pandemic planning,ACKNOWLEDGEMENTS,State and Local Health Departments WHOs Global Influenza Surveillance Network National Influenza Centers (esp. Mexico and Canadas NICs) WHO CCs WHO RO and HQ Influenza Division Staff, CDC Office of the Director Dan Jernigan
15、, Deputy Director Carolyn B. Bridges, Associate Director for Science Michael Shaw, Associate Director for Laboratory Science Epidemiology and Surveillance Branch Joe Bresee, Chief Immunology and Pathogenesis Branch Jackie Katz, Chief Viral Surveillance and Diagnostics Branch Alexander Klimov, Chief
16、Molecular Genetics Branch Ruben Donis, Chief CDC Pandemic H1N1 Response Team, Emergency Ops Center,Questions?,(NEJM submitted),CROSS-REACTIVE MN ANTIBODY RESPONSE IN ADULT RECIPIENTS (25-65 y.o.) OF 1976 INFLUENZA VACCINE (1976-77 INFLUENZA SEASON),ORIGIN OF THE 2009 PANDEMIC H1N1 VIRUS,ANTIGENIC MA
17、PPING (CDC, 54 antigens; 16 sera),HI REACTIONS OF PANDEMIC INFLUENZA H1N1v VIRUSES (CDC),HI REACTIONS OF PANDEMIC INFLUENZA H1N1v VIRUSES (CDC),HI REACTIONS OF PANDEMIC INFLUENZA H1N1v VIRUSES (NIID),TRANSMISSION EXPERIMENTAL DESIGN,RESPIRATORY DROPLET TRANSMISSION OF 2009 PANDEMIC INFLUENZA A(H1N1)
18、,PATHOGENESIS AND TRANSMISSIBILITY OF 2009 PANDEMIC INFLUENZA A(H1N1) VIRUSES IN FERRETS,Compared with seasonal A(H1N1) influenza, two novel H1N1 viruses caused Increased morbidity Replicated to higher titers in lung tissue Recovered from the intestinal tract of intranasally inoculated ferrets Resul
19、ts suggest higher virulence of novel H1N1 compared to seasonal H1N1 in the ferret model,KEY QUESTIONS REMAINING FOR EFFECTIVE 2009 H1N1 RESPONSE,Timing of expected fall wave of 2009 H1N1 in the NH? Timing and dosing for 2009 H1N1 monovalent vaccine, if recommended, based on clinical trial data? Target populations for 2009 H1N1 vaccine? Will reassortment occur with 0-resistant seasonal influenza viruses or with H5N1 viruses? How will antiviral drugs be used, assuming they are effective? Effectiveness of non-pharmaceutical interventions?,
